New Amsterdam Sciences, a privately held bioscience company, has taken up residence at Binghamton University’s Koffman Southern Tier Incubator, gaining access to advanced laboratories, expertise, and relationships, leveraging some of the very valuable services and networking the incubator has to offer. The move was prompted by the massive caseload for COVID-19 patients in the northeast, particularly New York and the CEO wanted to be close to where the studies would most likely take place. New Amsterdam is advancing the Company’s COVID-19 therapeutic agent candidate NAS150 into and through phase 2 clinical trials. The company will continue to hold offices in Scottdale, AZ.

“We are incredibly excited to advance our COVID-19 clinical candidate as well as our other candidates with the support of the relationship at The Southern Tier Incubator. It is an exceptional facility with state-of-the-art labs and offers us a unique level of mentorship and potential collaborations with to Binghamton University’s departments of biology and pharmacology,” said New Amsterdam Sciences’ CEO, Michael Wilhelm.” “Furthermore, it’s strategically located in Northern NY, giving the company access to the many healthcare facilities around the tri-state area.”

New Amsterdam Sciences will utilize the resources offered by Koffman Incubator to take its antioxidant and anti-inflammatory agent, the superoxide dismutase (SOD) mimetic NAS150, into Phase 2 clinical-stage trials as part of the FDA’s coronavirus treatment acceleration program.  

“We welcome New Amsterdam Sciences to Upstate, NY, and to the Koffman Incubator,” says Laura Holmes, director of operations at the Koffman Incubator. “Their innovations in bioscience, along with their growth, align with our mission to assist promising companies eager to gain support from a world-class staff, facility, and key connections in the region.”

New Amsterdam Sciences proposes that their Phase 2 clinical stage antioxidant and anti-inflammatory agent, the superoxide dismutase (SOD) mimetic NAS150, can be an effective treatment and co-therapeutic for SARS-CoV-2 infection. NAS150 is a Mn-metalloporphyrin SOD mimetic with demonstrated antioxidant and anti-inflammatory activity. It has been backed by sustained Federal R&D support and as a subcutaneous agent and is being positioned for administration via transdermal /microneedle patch as well as alternative routes. This clinical stage agent was shown to be effective in reducing oxidative stress, inflammation, and tissue damage following radiation injury and could be a single agent/adjuvant drug of choice for the treatment of patients soon after infection or with severe viral-infection-induced complications. Oxidative stress increases are a result of COVID-19 infection thus driving inflammation to become hyper-inflammation which typically triggers the cytokine release or “cytokine storm”. Modulating levels of oxidative stress and inflammation can enable a patient to effectively fight the virus and or the expected sequelae of symptoms that follow infection. NAS150 helps provide for this balance of the immune response. 

X